{"prompt": "['Alliance A171601', 'Drug Interactions', 'Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme', 'SULT2A1. Palbociclib interacts with CYP3A inhibitors and CYP3A inducers. Avoid', 'concurrent use of palbocic lib with strong CYP3A inhibitors or inducers.', 'Adverse Events', 'The following are common (> 10%) adverse events occurring in at least one patient who', 'received palbocic lib plus letrozole in clinical trials.', 'Infections and Infestations: Upper Respiratory Infection', 'Blood and Lymphatic System Disorders: Neutropenia, Leukopenia, Anemia, Thrombocytopenia', 'Metabolism and Nutrition Disorders: Decreased Appetite', 'Nervous System Disorders: Peripheral Neuropathy', 'Respiratory, Thoracic, and Mediastinal Disorders: Epistaxis', 'Gastrointestinal Disorders: Stomatitis, Nausea, Diarrhea, Vomiting', 'Skin and Subcutaneous Tissue Disorders: Alopecia', 'General Disorders and Administration Site Conditions: Fatigue, Asthenia', 'Nursing Guidelines', '1. Agent should be administered with food. Do not crush, break or open capsules prior to', 'administration.', '2. Monitor CBC w/diff as cytopenias are common and require dose reductions. Instruct', 'patients to report signs or symptoms of infection and/or any unusual bruising or', 'bleeding to the study team.', '3. GI symptoms are common, including nausea/vomiting, stomatitis and diarrhea. Treat', 'symptomatically and monitor for effectiveness. Some side effects may require dose', 'reductions.', '4. Patients should avoid grapefruit and grapefruit juice, due to possible increase in the', 'serum concentration of palbociclib.', '5. There are drug to drug interactions with CYP3A4 substrates. Obtain a complete list of', 'patient medications including OTC and herbal products. Instruct patients to report any', 'new mediations to the study team immediately.', '6. Warn patient of risk of thromboembolic events, specifically pulmonary embolism.', '7. Warn patients of possibility of alopecia.', '8. Patients may experience upper respiratory infection. Instruct patients to report URI', 'symptoms to study team.', '9. Rarely patients may experience peripheral neuropathy. Monitor patients closely who', 'may have preexisting CIPN from previous therapy.', '10.3 Fulvestrant', 'Please refer to the FDA-approved package insert for fulvestrant for product information,', 'extensive preparation instructions and a comprehensive list of adverse events.', 'Other names: Faslodex', '46', 'NCI Version Date: 5/29/2020', 'Update 5']['Alliance A171601', 'Classification: Estrogen receptor antagonist', 'Molecular Formula: C32H47F5O3S', 'M.W.: 606.77', 'Approximate Solubility: Each injection contains as inactive ingredients alcohol, USP, benzyl', 'alcohol, NF, and benzyl benzoate, USP as co-solvents and castor oil, USP as a co-solvent and', 'release rate modifier.', 'The solution is a clear, colorless to yellow, viscous liquid.', 'Procurement', 'Fulvestrant is a commercially available agent and filled with prescription.', 'Storage:', 'The syringes of fulvestrant for all cycles of treatment should be stored in the original container', 'and refrigerated at 2\u00b0 8\u00b0C (36\u00b0-46\u00b0F).', 'Administration:', 'Routes of Administration: IM Injection', 'Method of Administration: Remove glass syringe barrel from tray and check that it is not', 'damaged. Peel open the safety needle (SafetyGlide\u2122) outer packaging. Break the seal of the', 'white plastic cover on the syringe luer connector to remove the cover with the attached rubber', 'tip cap. Twist to lock the needle to the luer connector. Remove needle sheath. Remove excess', 'air from the syringe (a small gas bubble may remain).', 'For this study, fulvestrant will be administered at a dose of 500 mg (2 X 250 mg injections) IM', 'or as indicated per the package insert on Day 1 and Day 15 of Cycle 1 and then on Day 1 of', 'each cycle in each subsequent cycle. Administer intramuscularly slowly in the buttock. (NOTE:', '500 mg dose will require one 250 mg injection in each buttock.) Immediately activate needle', 'protection device upon withdrawal from patient by pushing lever arm completely forward until', 'needle tip is fully covered. Visually confirm that the lever arm has fully advanced and the needle', 'tip is covered. If unable to activate, discard immediately into an approved sharps container.', 'Toxicity:', 'The most common toxicities reported in trials of fulvestrant to date include gastrointestinal', 'symptoms, menopausal symptoms and injection site reactions. Nausea and vomiting have been', 'the primary GI symptoms, occurring in approximately 50% of patients in phase III trials. They', 'were generally of mild to moderate severity. Hot flashes were reported in approximately 20%', 'of patients. Injection site reactions inc lude pain, hemorrhage and inflammation. Such reactions', 'may be more frequent when fulvestrant is administered as 2 injections of 2.5 ml (125 mg) each,', 'as compared with 1 injection of 5 ml (250mg).', 'Potential Drug Interactions: In in vitro studies using human hepatocytes, fulvestrant was', 'metabolized predominantly by conjugation. The metabolites thus formed are thought to possess', 'no estrogenic activity and minimal anti-estrogenic activity. In studies using human liver', 'microsomes, fulvestrant inhibited the activity of CYP1A2, 2C9 and 3A4 minimally. CYP3A4', 'did metabolize fulvestrant in these studies, but the human hepatocyte studies noted above', 'indicate conjugation is a more important metabolic pathway. In addition, studies in healthy', 'volunteers indicate that fulvestrant metabolism is not significantly affected by inducers or', 'inhibitors of CYP3A4, nor does fulvestrant affect the metabolism of 3A4 substrates. Thus,', 'fulvestrant is not expected to be involved in significant drug interactions mediated by CYP3A4.', 'Nursing guidelines', '47', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}